614 news items
Page 3 of 31
e8wvh9cr40x6b3 n87bt2s8zffbpx6
10 Jun 24
Peptide Cancer Vaccine Market
nqg0kzn8l thj
10 Jun 24
clade of the H5N1 virus, we have designed a much-needed solution to aid avian influenza research, surveillance, vaccine development, and public health
1sqbktqcboox0bijaox nzeiwfy6jg6pgxmzy90k
ELTX
10 Jun 24
investigational Amphiphile (AMP) cancer vaccine that targets cancers that are driven by mutations in the mKRAS-gene — a prevalent driver of many human cancers
xx955w71dxkz21z oyi4k
BNTX
10 Jun 24
is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines
ynw4btptk 5e5
TLTFF
10 Jun 24
challenges, as proper uptake of the vaccine in bladder cancer cells requires the administration of high and multiple doses. The results presented today
z65h5vrcsec21m nh9
CLDI
SIGA
10 Jun 24
the RTNova platform for lung cancer and metastatic (or advanced stage) solid tumors which account for the majority of cancer deaths
xghdo3kq9dtln51zpfw1quyj1fiqh8iqi4cnjz1z02fr83ug3cqwf5zq
10 Jun 24
forging a new frontier in cancer vaccines. We are dedicated to revolutionizing cancer immunotherapy and focusing on difficult-to-treat diseases
py7xjz5
10 Jun 24
"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce its participation
tgf02umi qz1e6ic58rrq29na
GRTS
8 Jun 24
vaccine-based immunotherapy candidates against cancer and infectious diseases. For more information, submit
8iklechy7fyqrjflt 1j1wjfmarh
GRTS
7 Jun 24
]
Gritstone, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer
6cp862xd9lp33jmq8d60dh7
7 Jun 24
that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use
3yxvyhahkrglbhy8mx7jyzocms1srstv6fp4 zrb6rurgxs3a2
MRK
7 Jun 24
products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer
8mgkyoh20m4bzh7fc9c 729xa94cpb9m
7 Jun 24
Network at the World Vaccine Congress and received the 2022 Excellence in Patient Centricity Award from the Society for Clinical Research Sites (SCRS
t31mvu9etf6cqkfp1fwqq9puxdynnmcb8p63sihso4jwze3somy3130
IBRX
7 Jun 24
developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company's range
l2klcqvky12dl0hvsjoy0qx1l22aaksakrauocwxvx
SNGX
STSS
7 Jun 24
therapy for cutaneous T-cell lymphoma (CTCL), a rare chronic cancer, which has demonstrated positive results in a Phase 3 study published in JAMA
wwu7msasxx5mxwbvc1q0oq9lzyfbd9wbauw
CADL
7 Jun 24
cancer is treated, but just 20% to 40% of patients typically respond
7xfb787dcz2feffneq1e8a04q
AEMD
7 Jun 24
. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases
mf6l6u
PFE
6 Jun 24
drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular
3t0kt
6 Jun 24
vaccines, offer novel approaches to activate and enhance the immune response against cancer, leading to improved patient outcomes and prolonged survival
6bffa1rxbg0otwg10a cmm5k1
6 Jun 24
Therapy R&D Market Report 2024-2034: Forecasts by Disease (Cancer, Rare Diseases (Oncologic, Non-oncologic), Cardiovascular